Bora Pharmaceuticals announced the completion of its acquisition of MacroGenics’ GMP manufacturing operations for $122.5 million. The deal includes MacroGenics’ biologics drug substance facility in Rockville, Maryland, and an associated warehousing center in Frederick, Maryland. The transaction was completed through Bora Biologics USA, a wholly owned subsidiary of Bora Pharmaceuticals. Upon closing, Bora also signed a long-term CDMO service agreement with MacroGenics.